ICU Medical (ICUI) Expected to Announce Earnings on Thursday

ICU Medical (NASDAQ:ICUI) will likely be posting its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of $1.91 per share and revenue of $533.4420 million for the quarter. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Investors can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 EPS for the quarter, beating analysts’ consensus estimates of $1.78 by $0.19. The business had revenue of $525.77 million during the quarter, compared to analysts’ expectations of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The firm’s revenue was down 12.3% on a year-over-year basis. During the same period in the prior year, the company earned $1.72 earnings per share. On average, analysts expect ICU Medical to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

ICU Medical Trading Down 0.6%

Shares of ICU Medical stock opened at $171.96 on Wednesday. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.34 and a quick ratio of 1.17. The company’s fifty day simple moving average is $149.55 and its 200-day simple moving average is $140.57. The stock has a market capitalization of $4.30 billion, a PE ratio of 92.95, a P/E/G ratio of 2.42 and a beta of 0.74. ICU Medical has a 1-year low of $107.00 and a 1-year high of $176.27.

Analyst Ratings Changes

Several research firms recently issued reports on ICUI. Zacks Research lowered shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Jefferies Financial Group upgraded ICU Medical to a “strong-buy” rating in a research report on Thursday, May 7th. Needham & Company LLC raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a research note on Wednesday, May 27th. Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, BTIG Research assumed coverage on shares of ICU Medical in a report on Monday, June 15th. They issued a “buy” rating and a $170.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $172.00.

Insiders Place Their Bets

In other ICU Medical news, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the sale, the director directly owned 7,960 shares in the company, valued at approximately $978,363.60. This represents a 23.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total value of $303,623.76. Following the transaction, the vice president directly owned 19,460 shares in the company, valued at $2,414,596.80. The trade was a 11.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ICUI. Corient Private Wealth LLC raised its holdings in shares of ICU Medical by 1,299.9% in the 4th quarter. Corient Private Wealth LLC now owns 56,822 shares of the medical instruments supplier’s stock valued at $8,107,000 after purchasing an additional 52,763 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its stake in shares of ICU Medical by 89.9% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 4,815 shares of the medical instruments supplier’s stock valued at $687,000 after purchasing an additional 2,280 shares in the last quarter. EP Wealth Advisors LLC bought a new position in shares of ICU Medical during the fourth quarter valued at approximately $634,000. Mackenzie Financial Corp purchased a new position in ICU Medical during the fourth quarter valued at approximately $219,000. Finally, XTX Topco Ltd purchased a new position in ICU Medical during the fourth quarter valued at approximately $511,000. 96.10% of the stock is currently owned by institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.